Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 47

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 47
---
 such licenses obligate TELI to pay royalties to MIRALOGX even if TELI is not then earning revenue on the licensed products.

The members of the TELO Board were aware of and considered these interests in evaluating the Merger and in making the TELO Recommendation. The interests of TELO’s directors and executive officers are described in more detail in “ Interests of the TELO Directors, Executive Officers and Affiliate Shareholders in the Merger”on page 34 of this proxy statement.

The completion of the Merger is not conditioned on the receipt of an opinion of counsel to the effect that the Merger will qualify for the Intended Tax Treatment, and neither TELO nor TELI intends to request a ruling from the Internal Revenue Service regarding the U.S. federal income tax consequences of the Merger.

It is intended that, for U.S. federal income tax purposes, the Merger will constitute the Intended Tax Treatment (as defined below). However, the completion of the Merger is not conditioned on the Merger qualifying for the Intended Tax Treatment or upon the receipt of an opinion from counsel to that effect, and whether or not the Transaction will qualify for the Intended Tax Treatment depends on facts that will not be known until the Merger is completed. Finally, neither TELO nor TELI intends to request a ruling from the Internal Revenue Service regarding the U.S. federal income tax consequences of the Merger. Therefore, even if TELO concludes that the Merger qualifies for the Intended Tax Treatment, no assurance can be given that the Internal Revenue Service will not challenge that conclusion or that a court would not sustain such a challenge.

You should read “ Material U.S. Federal Income Tax Considerations” and consult your own tax advisors regarding the U.S. federal income tax consequences of the Merger to you in your particular circumstances.

| 25 |

TELO is subject to various uncertainties, including contractual restrictions and requirements while the Merger is pending, that could adversely affect their businesses, financial condition and results of operations.

During the pendency of the Merger, it is possible that commercial partners and/or other persons with whom TELO has a business relationship may elect to delay or defer certain business decisions or seek to terminate, change or renegotiate their relationships with TELO as a result of the Merger. Such events and actions could significantly reduce the expected benefits of the Merger and/or negatively affect TELO’s revenues, earnings and cash flows, TELO’s plans for commercialization and approval